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Abstract:  
Background and aims:  
Infection by hepatitis C virus is a worldwide health problem. An inadequate Th2 cytokine 
response promotes the fibrosis-cirrhosis fate. Immune-modulating molecules favoring a Th2 
profile, such as HLA-G molecules of the HLA class Ib family, may play a role in chronic 
hepatitis. HLA-G contributes to the escape of tumors, and their involvement in viral infections 
has been increasingly described. The aim of this work was to study the expression of HLA-G 
in the liver, its cellular source and its regulation in cases of chronic C hepatitis. 
Methods: HLA-G cells in blocks of liver derived from patients infected with HCV were 
labeled by immunohistochemistry and enumerated. Double immunofluorescence allowed the 
identification of the cellular source. HLA-G secretion by a human mast cell line was 
quantified by ELISA after various stimulations. After treatment with IFN- real-time PCR 
was performed to determine the kinetics of cytokine expression profiles, followed by heat 
map clustering analysis. 
Results: The number of HLA-G + cells was significantly associated with the area of fibrosis. 
For the first time, we identify the HLA-G+ cells as being mast cells. HLA-G secretion was 
significantly induced in human mast cells stimulated by IL-10 or interferons of class I. The 
transcriptome of the secretome of this cell line stimulated by IFN- revealed that i) the HLA-
G gene is upregulated late, ii) T lymphocytes and NK cells are recruited.  
Conclusions: These findings suggest an autocrine loop in the genesis of HCV liver fibrosis, 
based on mast cells expressing HLA-G.  
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Introduction 
Hepatitis C virus (HCV) infections are a worldwide public health problem. Infected patients 
may develop complications including cirrhosis, liver failure or hepatocellular carcinoma. The 
dynamics of fibrosis progression to cirrhosis is closely associated with chronic inflammation 
which is related to the efficiency of the immune response. Cytokines play a central role in the 
immune response and thus in orienting the fibrosis-cirrhosis fate [1].  
In cases of chronic hepatitis, cytokines, including TGF and some interleukins such as IL-4 
and IL-13, directly induce the production of extracellular matrix proteins and promote fibrosis 
[2]. Immune escape by HCV and progression of the infection towards chronicity are 
associated with the development of a Th2 response. These observations suggest that immune-
modulating molecules favoring a Th2 cytokine profile play a major role in chronic viral 
hepatitis. These factors may include HLA-G, a member of the HLA class Ib family, and 
which has membrane-bound and soluble (sHLA-G) forms which are immunomodulatory 
molecules. HLA-G was initially described at the fetal-maternal interface of the 
cytotrophoblast [3, 4]. Its immunomodulatory function has since been described [5] and its 
involvement in various pathologies, especially in malignancies, has been demonstrated [6]. 
HLA-G exhibits suppressive properties in various cells by inhibiting (i) the cytolytic function 
of NK cells and CD8 T cells and also triggering their apoptosis, (ii) the allo response of T4 
lymphocytes, (iii) the maturation and function of antigen-presenting cells, (iv) the 
proliferation and function of B cells and (v) angiogenesis. These functions are the 
consequence of the interaction between HLA-G and its receptors on immune cells, such as 
CD8, ILT2, ILT4, KIR2DL4 [7], or CD160 on endothelial cells [8]. HLA-G is also able to 
induce suppressor/regulatory cells [9, 10]. Its suppressive action is amplified by trogocytosis 
which allows effector cells to be converted into temporary regulatory cells [11]. HLA-G is 
involved in many malignant diseases, and participates in the escape of tumors by promoting a 
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Th2 cytokine environment and by inhibiting immune effector cells. Also, there is increasing 
evidence of the involvement of HLA-G in viral infections. Increased HLA-G expression, as 
membrane and/or soluble forms, has been evidenced in various types of viral infection, 
including those of human immunodeficiency virus (HIV) [12], human cytomegalovirus 
(HCMV) [13], neurotropic viruses (herpes virus and rabies virus) [14], influenza A virus [15] 
and hepatitis B virus [16].  
However, the expression and role of HLA-G in human chronic hepatitis C have not been 
thoroughly investigated. We therefore assessed HLA-G expression in liver tissues infected 
with HCV, and then identified its cellular source and studied its regulation. We show that 
HLA-G is expressed by some cells in hepatic tissue infected with HCV and that the number of 
HLA-G-positive liver cells is significantly correlated with the area of fibrosis. In addition, we 
identified the cell type expressing HLA-G as a subpopulation of mast cells. Finally, we show 
that HLA-G expression by mast cells is regulated by interferons of class I.   
 
Material and methods 
Tissues samples  
Liver biopsies from twenty chronically HCV-infected patients were retrospectively selected 
from the Biological Resource Center (BRC) of Rennes University Hospital. They were 
classified according to the METAVIR classification evaluating the severity of fibrosis (stage 
F0 to F4) and the inflammatory activity (A0 to A3). All biopsies were reviewed by an 
experienced pathologist. The characteristics of the patients are summarized in table 1. Non 
tumoral areas of the biopsies, away from the origin of the tumor, were used for all analyses. 
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 # Age Gender Metavir Etiology Pathology  
   F stage A stage   
1 49 M F4 A1 HCV HCC 
2 73 F F4 A1 HCV HCC 
3 72 M F1 A3 HCV HCC 
4 46 M F4 A1 HCV + HBV + HIV HCC 
5 56 F F4 A1 HCV HCC 
6 56 F F4 A0 HCV HCC 
7 62 M F4 A1 HCV HCC 
8 47 M F4 A1 HCV Transplantation  
9 73 F F4 A1 HCV HCC 
10 84 M F4 A1 HCV HCC 
11 55 M F2 A1 HCV HCC 
12 51 F F4 A1 HCV HCC 
13 83 F F4 A1 HCV HCC 
14 40 M F4 A1 HCV + HBV HCC 
15 49 F F4 A0 HCV + HIV HCC 
16 65 F F4 A0 HCV HCC 
17 55 M F4 A1 HCV HCC 
18 75 M F3 A1 HCV + alcohol HCC 
19 75 M F4 A2 HCV No 
20 67 M F4 A1 HCV HCC 
Table 1. Characteristics of the HCV patients. 
 
Cell cultures  
The following cell lines were used as a positive control for HLA-G expression: Jeg3 
(American Type Culture Collection (ATCC)), and LCL.721.221-G5, a B lymphoblastoid cell 
line transfected with HLA-G5 (D. Geraghty, Fred Hutchinson Cancer Research Center) as 
previously described [17]. The human mast cell line used, HMC1.1 (a generous gift from Dr 
Butterfield, Mayo clinic, Rochester), was established from a patient with mast cell leukemia 
as previously described [18]. HMC1.1 cells (106 cells /ml) were cultured in six-well culture 
plates in IMDM medium (Iscove Modified Dubelcco Medium, Gibco life technologies, Cergy 
Pontoise, France) at 37°C with 5% CO2 for 48 hours. The effects of the presence of the 
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following cytokines, supplied by Peprotech-Tebu Bio (Neuilly, France), were tested: IL-33 
(100ng/ml), IL-31 (50ng/ml), IL-4 (50ng/ml), IL-6 (50ng/ml), TNF- (10ng/ml), Oncostatin 
M (OSM) (50ng/ml), IL-1 (10 ng/ml), IL-10 (50ng/ml), TGF- (5ng/ml), IL-22 (10ng/ml), 
IFN-(50ng/ml), IFN-(50ng/ml), IFN-(50ng/ml), IFN-(10ng/ml), IFN-1 (50ng/ml), 
and IFN-2 (50ng/ml).  
 
Immunohistochemistry 
Standard histological staining, including Sirius red staining of collagen accumulation and 
HES coloration, was performed. Paraffin-embedded sections (4µm thick) were prepared, 
subjected to an antigen retrieval protocol, and incubated with primary antibody in a Ventana 
CT 09/021 automated machine (Ventana Medical systems, USA). Primary antibodies and 
dilutions used were: monoclonal mouse anti-human hepatocyte (clone OCH1E5, Dako, 
1:600), mouse monoclonal anti-human HLA-G (Exbio, 4H84, 2 µg/ml), monoclonal mouse 
anti-human HLA-G (Exbio, MEM-G/1, 1µg/ml or 1:100), rabbit monoclonal anti-human CD3 
(Thermo Scientific, SP7, 1:1500), mouse monoclonal anti-human CD163 recognizing liver 
macrophages (Novocastra, 10 D6, 1:500), polyclonal rabbit anti-human CD117/ckit 
recognizing myeloid cells (Dako, 1:200), and mouse monoclonal anti-human mast cell 
tryptase (clone AA1, Dako, 1:1000). Bound primary antibody was revealed with goat 
biotinylated anti-mouse or anti-rabbit IgG secondary antibody (Vector, ABCYS, Les Ulis, 
France, 1:700) and then diamino-benzidine (DAB Map Detection Kit, Roche, Meylan, 
France) and Mayer hematoxylin coloration.  
After immunohistochemistry, the image of whole surface of the section was digitized at 20 X 
magnification using a NanoZoomer Digital Pathology 2.0 RS whole-slide scanner 
(Hamamatsu, Japan). An appropriate computer script analysis was developed and used for 
semi automatic enumeration of HLA-G+ cells and MCs or CD3+ T cells. The area of fibrosis 
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was evaluated by annotation. Fibrosis areas were drawn on the whole section and the surface 
area was calculated using “simple PCI” software. As direct HLA-G/ human mast cell tryptase 
double immunofluorescence was not possible because of antibody incompatibility, two double 
indirect immunofluorescence experiments, sharing CD117 (CD117/HLA-G and CD117/anti 
human mast cell tryptase) were performed in parallel on serial sections of paraffin-embedded 
sections from the same liver block. For immunofluorescence detection, fluorochrome-
conjugated secondary antibodies (Jackson ImmunoResearch, Cy5- affinipure donkey anti-
mouse IgG and Cy3-affinipure donkey anti-mouse IgG) were incubated with the sections for 
1h at room temperature. Nuclei were counterstained with Hoechst stain (Molecular probe).  
 
Specific Soluble HLA-G Enzyme-Linked Immunosorbent Assay 
Soluble HLA-G concentrations in HMC1.1 culture-conditioned media were measured by 
specific sandwich enzyme-linked immunosorbent assay (ELISA) using MEM-G/9 (Exbio, 
Prague, Czech Republic; 10 µg/ml) and rabbit anti human beta-2 microglobulin (Dako, 
Trappes, France) as capture and revelation antibodies, respectively, as previously described 
[19] with minor modifications: after the second Ab, DAKO envision system HRP was added 
and  tetramethylbenzidine/peroxide (TMB, R&D system) was used as the substrate.  
 
Quantification of chemokine gene expression by real-time quantitative PCR 
After various times of stimulation of HMC1.1 cells with IFN- total RNA was extracted and 
purified with the Nucleospin RNA II Kit R (Macherey-Nagel, Hoerdt, France). The High 
capacity cDNA archive Kit R (Applied Biosystems, Cergy Pontoise, France) was used for 
reverse transcription of aliquots of 3 µg of total extracted RNA following the manufacturer’s 
instructions. Primers having the same melting temperature (Tm) were designed using Primer3 
software. A large panel of cytokines and chemokines was tested using a large-scale qPCR 
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approach as shown in Fig. 4C. Real-time PCR for HLA-G was performed in parallel with the 
same samples and with the HLA-G-positive cell line, Jeg3, using primers designed according 
the same methodology (Fig. S1.). The CT method was used for quantification of the 
housekeeping genes 18S, GAPDH, and SDHA used for multiple normalization as described 
previously [20]. To ensure that the primers produced a single and specific PCR amplification 
product, a dissociation curve was determined during PCR cycles. Dissociation curves were 
checked and in all cases showed a single dissociation peak; products were also tested by 
migration on 2% agarose gel to ensure that there was only one single PCR product in each 
reaction (Fig. S2.). The expression level of each gene was adjusted to the level of 
housekeeping gene mRNAs (18S mRNA, GAPDH mRNA and SDHA mRNA) and is 
expressed as the mean of the three ratios (mean of the gene to house keeping gene ratios). 
Gene expression was evaluated as a function of the time of stimulation, so results are 
expressed as 2 – Ct referred to as the fold induction in relation to the mean Ct at time 0.  
 
qPCR data clustering 
The Annotation, Mapping, Expression and Network (AMEN) suite of tools was used for 
cluster analysis [21]. After a log2 transformation of the qPCR data, genes with the most 
similar expression profiles were classified into four groups (k=4) using the Partition Around 
Medoids (PAM) algorithm implemented in AMEN. 
 
Statistical analyses: Statistical analyses were performed with GraphPad prism software and 
included the Spearman test and Student’s t test. 
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Results 
HLA-G expression is correlated with HCV-induced liver fibrosis. 
To test for HLA-G in HCV-induced liver fibrosis, we used immunohistochemistry with anti-
HLA-G (clone 4H84) to probe serial sections of paraffin-embedded liver. The area of fibrosis 
was evaluated by sirius red staining and hepatocyte nodules identified by specific anti-
hepatocyte labeling (clone OCH1E5) (Fig. 1.A). We observed a strong HLA-G staining of 
numerous cells in fibrosis septa but not in hepatocyte nodules (Fig. 1.B). Each HLA-G 
positive cell had a large and granular cytoplasm. Similar patterns of staining were obtained 
using another anti-HLA-G antibody (clone MEM-G/1) (Fig. 1.C). The HLA-G-positive cell 
count and the area of fibrosis across the whole surface of the liver section were significantly 
and positively correlated (Spearman’s test, r = 0.5017, p<0.05, n=20) (Fig. 1.D). In this series, 
therapy, and in particular with IFN- did not influence this correlation: if the two treated 
patients in our series were excluded from the analysis, the HLA-G-positive cell count and the 
area of fibrosis across the whole surface of the liver section were still significantly correlated 
(Spearman’s test, r = 0.6102, p<0.05, n=18).   
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 Fig. 1. Expression of HLA-G in HCV liver fibrosis. (A) Sirius red staining of collagen accumulation 
and staining of hepatocyte modules with anti-hepatocyte antibodies in a representative case. (B) 4H84 
Labeling is located in fibrosis septa and not in areas composed of hepatocytes. (C) Comparison 
between 4H84 and MEM-G/1 staining. (D) Correlation between HLA-G+ cell numbers and fibrosis 
area expressed in mm2 according to the Spearman test (r = 0.5017, p <0.05, n = 20). 
 
To investigate the relation between expression of HLA-G and inflammatory activity, the 
number of CD3 T cells detected over the entire surface of the liver section was counted. The 
number of HLA-G positive cells and that of CD3 T lymphocytes were positively and 
significantly correlated (Spearman‘s test, r = 0.7273, p<0.05) (Fig. S.1.). 
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HLA-G positive cells in HCV-induced liver fibrosis are mast cells.  
To identify the cell type expressing HLA-G, we used anti-CD3, anti-CD163, anti-CD117, 
anti-mast cell tryptase (clone AA1) and anti-HLA-G (clone 4H84) antibodies to visualize T 
lymphocytes, liver macrophages (Kupffer cells), myeloid cells and mast cells (Fig. 2.B). 
Topographically and cytologically, we excluded T lymphocytes, macrophages and Kupffer 
cells as HLA-G positive cells. In contrast, cells presenting morphological features similar to 
those positive for HLA-G labeling stained positive for anti-CD117, a marker of mast cells. To 
test whether HLA-G is expressed by mast cells in liver fibrosis, we used anti-HLA-G and 
anti-mast cell (clone AA1) antibodies on serial liver sections from 20 patients. Consistent 
with the results with anti-CD117, the anti-mast cell antibody stained cells presenting 
morphological features similar to those showing HLA-G labeling, located in fibrotic areas. 
Mast cell counts and HLA-G-positive cell counts were significantly correlated (Spearman 
test: r= 0.7083, p =0.0005, n= 20) (Fig. 2.C), with 15 ± 7 HLA-G positive cells and 51 ± 34 
mast cells per 1 mm2 of fibrotic area.  
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 Fig. 2.  Pattern of HLA-G expression with morphological characteristics in human HCV fibrosis 
liver. (A) Representative Sirius red staining of collagen accumulation and staining of hepatocyte 
modules with anti-hepatocyte Ab. (B) Representative immunohistochemical analysis of HLA-G, CD3, 
CD163, CD117, and human mast cells in fibrosis and hepatocyte areas. (C) Positive correlation 
between the number of HLA-G+ cells and the number of mast cell according Spearman test 
(r = 0.7083, p <0.01, n = 20). 
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The commercially available antibodies are not compatible for use in straightforward double 
immunostaining experiments. Therefore, to confirm that the cells expressing HLA-G in liver 
fibrosis are hepatic mast cells, we performed two double indirect immunofluorescence tests 
with one shared antibody, anti-CD117, on pairs of serial sections (Fig. 3.B). The CD117-
positive cells expressed both HLA-G and tryptase. This demonstrates that a subpopulation of 
hepatic human mast cells is HLA-G positive (defined as HLA-G+CD117+tryptase+) (Fig. 3. 
B1 and B2).  
 
Fig. 3. HLA-G+ liver cells identified as mast cells by double immunofluorescence. (A) Double 
staining for CD117/HLA-G and CD117/human-mast cell tryptase was performed on pairs of serial 
sections from paraffin-embedded liver blocks. The same double-positive cell stained yellow, indicated 
by an arrow, is first identified within a region of double-positive stained cells (at magnification 100× 
and 400×) with CD117/HLA-G (labeled 1) and CD117/human mast cell tryptase (labeled 2). (B) B1 
and B2 at magnification 1000×. Nuclei were stained blue with Hoechst 33348; CD117 was identified 
by green fluorescence and HLA-G or mast cells by red fluorescence; CD117 colocalized with HLA-G 
and CD117 also colocalized with h-mast cells. Thus, HLA-G co-localized with h-mast cells. 
 
Soluble HLA-G secretion is regulated by type I interferons in mast cells 
To assess the regulation of HLA-G secretion by mast cells, we used the human mast cell line 
HMC1.1 and cultures of these cells were induced with various cytokines known to be 
associated with the immunopathology of HCV. After 48 hours of stimulation, conditioned 
medium was tested for secreted HLA-G by specific ELISA. IL-33, IL-31, IL-4, IL-6, TNF, 
OSM, IL-1 TGFand IL-22 did not increase HLA-G secretion (Fig. 4.A). IL-10 induced a 
significant increase of the HLA-G concentration in the medium (7.8 ng/ml versus 4.0 ng/ml in 
unstimulated controls, n=5; Student’s t test: p<0.05). Various interferons were tested, and the 
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class I interferons IFN-IFN-and IFN-induced a significant increase of HLA-G 
secretion (11.7 ng/ml for IFN- and IFN-, and 15.3 ng/ml for IFN- versus 3.0 ng/ml for 
controls) whereas the class II interferon IFN-and class III interferons IFN-1 and IFN-2 
had no significant effects (Fig. 4.B). 
 
Fig. 4. Regulation of HLA-G expression by the human mast cell line HMC1.1. The control (Ctrl) 
corresponding to the cell line before any stimulation is arbitrarily assigned a value of 1. (A) 
Stimulation of HMC1.1 by various cytokines: IL-10, IL-33, IL-31, IL-4, IL-6, TNF-α, OSM, IL-1β, 
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IL-22. Results from at least three independent experiments are presented. Significant expression was 
noted (p <0.05). (B) Stimulation of HMC1.1 by various interferons of the three classes: type I 
interferons IFN-α,β,ω, the type II interferon IFN-γ, and the type III interferons IFN-λ1 and IFN-λ2. 
Significant expression was noted thus: p <0.001, p <0.0001. (C) Cluster analysis of cytokine 
gene expression by HMC1.1 after various times of stimulation with IFN-α (4 h, 8 h, 24 h, and 48 h) 
relative to the baseline value (0 h) before addition of IFN-α. Panel C shows a false-color heatmap of 
genes (y-axis) having an altered expression pattern after IFN-α stimulation at the time points given (x-
axis). Genes are grouped into four clusters (termed I, II, III, and IV) according to their relative 
expression levels at different time points. Dendrogram plots based on the hierarchical clustering of 
each individual group are displayed to the right. Briefly, groups I, II, and III and include genes 
upregulated after IFN-α stimulation but differing according to the time of increase, whereas group IV 
represents genes downregulated by IFN-α stimulation. The color scale bar to the bottom of the 
heatmap indicates log2-ratio (blue = down-regulation, white = no change in expression, red = up-
regulation). 
 
To determine whether this regulation by IFN- involved only soluble forms or membrane-
bound forms, HLA-G expression on the surface of HMC1.1 cells was determined by flow 
cytometry with the antibody 87G, a specific conformational anti-HLA-G antibody. This 
expression was determined after 0, 4, 8, 24, and 48 hours of IFN- stimulation, and 
intracellular expression was studied at the same timepoints by immunocytochemistry and 
western blotting (Fig. S.3.). We found strong cell surface expression of HLA-G associated 
with intracellular expression by HMC1.1 cells at baseline (hour 0), which was confirmed by 
western blot analysis. Cell surface expression as assessed by flow cytometry did not 
significantly increase with stimulation with IFN-, whether scored as % positivity or MFI 
(mean of MFI ratio =6, range 5.7 to 6.8). Immunohistochemical observation revealed that the 
extent of labeling of the HMC1.1 cells was very diverse: some cells were strongly labeled, 
some partially labeled and some only weakly labeled (Fig. S.3).   
In toxicity and proliferation assays, there were no significant differences in the numbers of 
HMC1.1 cells between the IFN--stimulated and control conditions (Fig. S. 4). Furthermore, 
the response of HMC1.1 cells to IFN- treatment was dose- and time-dependent (Fig. S.4.). 
To study the profile of cytokines expressed by mast cells concomitantly with HLA-G during 
IFN- stimulation, the transcripts of 81 cytokine genes were assayed by real-time PCR after 
4, 8, 24 and 48 hours of stimulation by IFN-. Cluster analysis identified four groups of genes 
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in addition to the group of 19 genes not responsive to IFN- (IL-1, IL-, IL-2, IL-3, IL-17; 
IL-17B, IL-17D, IL21, IL-12p35, IL-12p40, IL-31, IFN-, CCL17, CCL19, CCL21, CCL22, 
CXCL1, CXCL2 and CXCL5) (data not shown). The first group, termed cluster I, included 16 
genes that were up-regulated by IFN-in a continuous manner; OSM, IL-33, TGF- and IL-6 
belonged to this cluster I (Fig. 4.C). The second group (cluster II) included 21 genes up-
regulated at 4 and 8 hours but with a decreased expression from 24 hours (Fig. 4C). The third 
group (cluster III) contained eight genes, including HLA-G, that were up-regulated by IFN-
at late time points (Fig. 4.C). Finally, the fourth group (cluster IV) included 16 genes that 
were down-regulated during IFN- stimulation (Fig. 4.C). Thus, nine cytokines (CCL25, 
CXCL10, XCL1, CCL24, CXCL13, IL-29, IL-33, IL-5, CCL13) were up-regulated by IFN-
concomitantly with HLA-G in the mast cell line HMC1.1 (Table 2). 
     Induction Receptor Target cells 
CCL25 6.85 CCR9 T lymphocytes 
CXCL10 7.38 CXCR3  T lymphocytes, NK cells 
XCL1 7.65 XCR1 ? 
CCL24 9.23 CCR3 T lymphocytes, NK cells 
CXCL13 7.81 CXCR5 B lymphocytes 
IL-29/IFN-2  5.17 IFN-R Host defense against virus 
IL-33 3.28 IL-33R T helper, mast cells  
IL-5 7.85 IL-5R B cells 
CCL13 9.72 CCR2  monocytes 
 
Table 2. Chemokine and cytokine genes induced in mast cells by IFN-α stimulation, and their 
receptors and cell targets. 
 
 
Discussion 
HLA-G was initially described at the maternal-fetal interface [4]. It was subsequently found 
to contribute to tumor escape due to its tolerogenic properties involving the inhibition of 
various immune-competent cells such as NK cells, T lymphocytes, B lymphocytes and 
dendritic cells [6]. Various recent evidence shows that HLA-G is induced by viral infection. 
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Blood HLA-G titers are high in most cases of HIV [12], HCMV [22], HBV [16] and HCV 
[23] infection, and in the majority of viral infections, HLA-G is expressed by blood cells, 
notably monocytes and/or T lymphocytes [15]. 
Here, we show that in human livers infected by HCV, HLA-G is associated with the 
progression of fibrosis; the number of HLA-G-positive cells correlated significantly with the 
area of fibrosis on tissue sections. By immunohistochemical analysis, we identified the cell 
type expressing HLA-G in liver samples from HCV-positive patients. In contrast with other 
reports of analyses of tumors and viral infections, we found that the monocytic lineage, i.e. 
monocytes [24], dendritic cells [25] and T lymphocytes [26, 27], in HCV-induced liver 
fibrosis does not express HLA-G. Also, we did not find that hepatocytes are specifically 
stained (Fig. 1 and Fig. 2), as previously reported by Donadi et al [28], possibly due to the 
lower concentration of antibody 4H84 used. Morphological observations (the large and 
granular cytoplasm) and immunostaining approaches with anti CD117 and anti-mast cell 
tryptase, indicate that cells expressing HLA-G in HCV-induced liver fibrosis are mast cells. 
Also, the number of HLA-G positive mast cells correlated with the area of fibrosis. It was 
recently shown that the number of mast cells increases during the course of chronic HCV-
related disease [29], [30]. Mast cells play a role in acute and chronic inflammation promoting 
fibrosis in heart [31], lung [32] and kidney [33] and in the secretion of histamine, heparin and 
IL-4 able to enhance fibroblast proliferation and collagen deposition [34]. Mast cells also 
inhibit degradation of the extra cellular matrix by producing tissue inhibitors of 
metalloproteinase [29]. Mast cells have traditionally been linked to immunoglobulin E-
hypersensitivity, asthma and host defense against parasites [35]. As is the case in almost all 
tissues, in HCV-induced liver fibrosis, the hepatic mast cells may serve as sentinels for 
immune responses and directly promote the activation of the liver fibrosis through the 
proliferation of hepatic stellate cells (HSC) [34]. HSC can produce TGF- which is a potent 
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mast cell chemoattractant [36] [37] and this may explain the presence of mast cells in liver 
fibrosis. Other cytokines, such as IL-4 and IL-33, involved in liver fibrosis may also explain 
the chemoattractant and activation of mast cells in liver [51, 52]. 
We used the HMC1.1 cell line to study the regulation of HLA-G by 16 cytokines. We 
identified IL-10 as a potential inducer of HLA-G in mast cells. This is consistent with 
previous reports of induction of HLA-G expression in trophoblasts and monocytes [38] and in 
some tumoral pathologies [39]. Furthermore, it was recently shown that murine mast cells can 
secrete IL-10 [40]. IL-10 is an immunoregulatory cytokine that plays a key role in progression 
to chronic HCV infection [41]. Interferons of classes II and III had no effect on the secretion 
of HLA-G by mast cells. By contrast, class I IFNs, including IFN,  and , induced 
secretion of HLA-G. There is an apparent discrepancy between the increased production of 
the soluble form and absence of change in the abundance of the membrane-bound form after 
IFN- treatment as evaluated by flow cytometry. This could be a consequence of the 
susceptibility of HLA-G1 to cleavage by metalloproteinases resulting in soluble forms 
detected by ELISA but not on the cell surface by flow cytometry. Indeed, IFN- may favor 
proteolytic cleavage by acting on the cleavage site. IFN and  are known to induce HLA 
class I expression in monocytes and many tumoral cells by binding with the interferon-
stimulated response element (IRSE) motif [42]. IFN- and , and class III IFNs are induced 
by HCV and constitute the main anti-HCV viral response of the host. Thus, during the 
evolution of HCV-induced liver fibrosis, IFN- produced in response to HCV attack may 
induce HLA-G in mast cells in areas of fibrosis. 
To investigate the cytokine microenvironment, we measured cytokine and chemokine 
transcripts expressed concomitantly with that of HLA-G after IFNinduction. CCL25, 
CXCL10, XCL1, CCL24, CXCL13, IL-29, IL-33, IL-5 and CCL13 were up-regulated by 
IFN-concomitantly with HLA-G, suggesting that these cytokines and chemokines are 
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present in or around areas of fibrosis. Using various investigative approaches 
(immunohistochemistry, quantitative PCR and DNA microarrays), the production of most of 
these cytokines has already been found to be associated with HCV liver fibrosis [1, 43] and 
the expression of some of them by mast cells has been reported [44-47]. The expression of 
these nine cytokines concomitantly with HLA-G defines leukocyte recruitment involving T 
lymphocytes, NK cells and to a lesser degree B lymphocytes and monocytes (table 2); all 
these cell types are known to infiltrate HCV-induced liver fibrosis.  Furthermore, the human 
mast cell line expresses an HLA-G receptor, ILT2 (Fig. S3), suggesting an autocrine loop.   
This type of regulation with concomitant HLA-G and ILT4 expression has been suggested in 
dendritic cells or monocytes [5]. HLA-G can control the expression of it own receptors on 
antigen presenting cells (APC), T cells and NK cells [48].  Similarly, it was shown that HLA-
G acts in an autocrine regulatory feedback loop in HIV infection: it is secreted by dendritic 
cells and regulates the functional characteristics of these cells via interaction with its receptor, 
ILT4 [49]. 
 
In conclusion, our data show clearly that HLA-G is expressed by mast cells in fibrotic areas of 
liver from patients infected with HCV, and that IFN-produced in response to HCV infection 
up-regulates the secretion of HLA-G. However, the function of HLA-G during HCV infection 
remains to be described. HLA-G may promote viral escape from the immune system, as in 
cancers, by inhibiting both adaptive and innate immunity, such that HCV-infected cells would 
be protected and viral progression favored. Another possibility is that, like in septic shock, 
HLA-G expression reflects an appropriate and efficient response to inflammatory processes 
occurring during viral infection. Indeed, HLA-G may have different roles according to the 
stage of infection: deleterious at the beginning of the chronic process of hepatitis, and 
protective during the stage of established fibrosis. The effects need to be interpreted in 
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relation with those of the mast cells, the cells expressing HLA-G. Further work is needed to 
elucidate the respective roles of HLA-G and mast cells in the genesis and the evolution of 
liver fibrosis.  
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Table 1: The characteristics of the HCV patients  
# Age Gender Metavir Etiology Pathology  
   F stage A stage   
1 49 M F4 A1 HCV HCC 
2 73 F F4 A1 HCV HCC 
3 72 M F1 A3 HCV HCC 
4 46 M F4 A1 HCV + HBV + HIV HCC 
5 56 F F4 A1 HCV HCC 
6 56 F F4 A0 HCV HCC 
7 62 M F4 A1 HCV HCC 
8 47 M F4 A1 HCV Transplantation  
9 73 F F4 A1 HCV HCC 
10 84 M F4 A1 HCV HCC 
11 55 M F2 A1 HCV HCC 
12 51 F F4 A1 HCV HCC 
13 83 F F4 A1 HCV HCC 
14 40 M F4 A1 HCV + HBV HCC 
15 49 F F4 A0 HCV + HIV HCC 
16 65 F F4 A0 HCV HCC 
17 55 M F4 A1 HCV HCC 
18 75 M F3 A1 HCV + alcohol HCC 
19 75 M F4 A2 HCV No 
20 67 M F4 A1 HCV HCC 
 
 
24 
Table 2: Chemokine and cytokine genes induced in mast cells by IFN- stimulation, and 
their receptors and cell targets. 
 
     Induction Receptor Target cells 
CCL25 6.85 CCR9 T lymphocytes 
CXCL10 7.38 CXCR3  T lymphocytes, NK cells 
XCL1 7.65 XCR1 ? 
CCL24 9.23 CCR3 T lymphocytes, NK cells 
CXCL13 7.81 CXCR5 B lymphocytes 
IL-29/IFN-2  5.17 IFN-R Host defense against virus 
IL-33 3.28 IL-33R T helper, mast cells  
IL-5 7.85 IL-5R B cells 
CCL13 9.72 CCR2  monocytes 
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Legends 
Figure 1. Expression of HLA-G in HCV liver fibrosis. (A) Sirius red staining of collagen 
accumulation and staining of hepatocyte modules with anti-hepatocyte antibodies in a 
representative case. (B) 4H84 labeling is located in fibrosis septa and not in areas composed 
of hepatocytes. (C) Comparison between 4H84 and MEM-G/1 staining. (D) Correlation 
between HLA-G+ cell numbers and fibrosis area expressed in mm2 according to the 
Spearman test (r=0.5017, p<0.05, n=20).  
 
Figure 2. Pattern of HLA-G expression with morphological characteristics in human 
HCV fibrosis liver (A) Representative Sirius red staining of collagen accumulation and 
staining of hepatocyte modules with anti-hepatocyte Ab. (B) Representative 
immunohistochemical analysis of HLA-G, CD3, CD163, CD117, and human mast cells in 
fibrosis and hepatocyte areas. (C) Positive correlation between the number of HLA-G+ cells 
and the number of mast cell according Spearman test (r=0.7083, p<0.01, n=20). 
 
Figure 3. HLA-G+ liver cells identified as mast cells by double immunofluorescence. (A) 
Double staining for CD117/HLA-G and CD117/human-mast cell tryptase was performed on 
pairs of serial sections from paraffin-embedded liver blocks. The same double-positive cell 
stained yellow, indicated by an arrow, is first identified within a region of double-positive 
stained cells (at magnification 100 x and 400x) with CD117/HLA-G (labeled 1) and 
CD117/human mast cell tryptase (labeled 2), (B) B1 and B2 at magnification 1000. Nuclei 
were stained blue with Hoechst 33348; CD117 was identified by green fluorescence and 
HLA-G or mast cells by red fluorescence; CD117 colocalized with HLA-G and CD117 also 
colocalized with h-mast cells. Thus, HLA-G co-localized with h-mast cells.  
 
Figure 4. Regulation of HLA-G expression by the human mast cell line HMC1.1  
The control (CTRL) corresponding to the cell line before any stimulation is arbitrarily 
assigned a value of 1. (A) Stimulation of HMC1.1 by various cytokines: IL-10, IL-33, IL-31, 
IL-4, IL-6, TNF OSM, IL-1, IL-22. Results from at least three independent experiments 
are presented. * Significant expression was noted (p<0.05). (B) Stimulation of HMC1.1 by 
various interferons of the three classes: type I interferons IFN, the type II interferon 
26 
27 
IFN-, and the type III interferons IFN-and IFN-2. Significant expression was noted 
thus: p<0.05 = *, p<0.001 = **, p<0.0001=***. (C) Cluster analysis of cytokine gene 
expression by HMC1.1 after various times of stimulation with IFN- (4h, 8h, 24h, and 48) 
relative to the baseline value (0h) before addition of IFN- Panel C shows a false-color 
heatmap of genes (y-axis) having an altered expression pattern after IFN- stimulation at the 
time points given (x-axis). Genes are grouped into four clusters (termed I, II, III and IV) 
according to their relative expression levels at different time points. Dendrogram plots based 
on the hierarchical clustering of each individual group are displayed to the right. Briefly, 
groupsand  include genes upregulated after IFN- stimulation but differing according 
to the time of increase, whereas group IV represents genes downregulated by IFN- 
stimulation. The color scale bar to the bottom of the heatmap indicates log2-ratio 
(blue=down-regulation, white=no change in expression, red=up-regulation). 
